Literature DB >> 10408698

Effect of intraperitoneally administered recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells.

A H Klimp1, J Regts, G L Scherphof, E G de Vries, T Daemen.   

Abstract

We studied the effect of recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells. Mice received rmGM-CSF intraperitoneally using different dosages and injection schemes. At different time points after the last injection, mice were sacrificed, peritoneal cells isolated and their tumour cytotoxicity was determined by a cytotoxicity assay using syngeneic [methyl-3H]thymidine-labelled colon carcinoma cells. Also, the cytotoxic response to a subsequent in vitro stimulation with lipopolysaccharide was determined. Upon daily injection of 6000-54,000 U rmGM-CSF over a 6-day period, the number of peritoneal cells increased over ten fold with the highest rmGM-CSF dose. Increases in cell numbers was mainly due to increases in macrophage numbers. Upon injection of three doses of 3000 U rmGM-CSF per day for 3 consecutive days, the number of macrophages remained elevated for minimally 6 days. Although the peritoneal cells from rmGM-CSF-treated mice were not activated to a tumoricidal state, they could be activated to high levels of cytotoxicity with an additional in vitro stimulation of lipopolysaccharide. Resident cells isolated from control mice could be activated only to low levels of tumour cytotoxicity with lipopolysaccharide. Tumour cytotoxicity strongly correlated with nitric oxide secretion. When inhibiting nitric oxide synthase, tumour cell lysis decreased. Thus, the expanded peritoneal cell population induced by multiple injections of rmGM-CSF has a strong tumour cytotoxic potential and might provide a favourable condition for immunotherapeutic treatment of peritoneal neoplasms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408698      PMCID: PMC2362159          DOI: 10.1038/sj.bjc.6690016

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

Review 1.  Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis.

Authors:  I J Fidler
Journal:  Res Immunol       Date:  1992-02

2.  Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor.

Authors:  K H Grabstein; D L Urdal; R J Tushinski; D Y Mochizuki; V L Price; M A Cantrell; S Gillis; P J Conlon
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

3.  Mouse peritoneal macrophages: characterization of functional subsets following Percoll density gradients.

Authors:  N Plasman; B Vray
Journal:  Res Immunol       Date:  1993-02

4.  Hematologic effects of recombinant murine granulocyte-macrophage colony-stimulating factor on the peripheral blood and bone marrow.

Authors:  T R Ulich; J del Castillo; I McNiece; L Watson; S M Yin; J Andresen
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

5.  Induction of murine peritoneal macrophage colony-forming cells by peritoneal administration of macrophage inflammatory protein-1 alpha.

Authors:  B Chen; T H Chou; L Sensenbrenner
Journal:  Exp Hematol       Date:  1993-11       Impact factor: 3.084

6.  Taxol provides a second signal for murine macrophage tumoricidal activity.

Authors:  C L Manthey; P Y Perera; C A Salkowski; S N Vogel
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

7.  Endocytic and tumoricidal heterogeneity of rat liver macrophage populations.

Authors:  T Daemen; A Veninga; F H Roerdink; G L Scherphof
Journal:  Sel Cancer Ther       Date:  1989

8.  Hemopoietic responses in mice injected with purified recombinant murine GM-CSF.

Authors:  D Metcalf; C G Begley; D J Williamson; E C Nice; J De Lamarter; J J Mermod; D Thatcher; A Schmidt
Journal:  Exp Hematol       Date:  1987-01       Impact factor: 3.084

9.  Effects of long-term in vivo treatment of mice with purified murine recombinant GM-CSF.

Authors:  Z Pojda; G Molineux; T M Dexter
Journal:  Exp Hematol       Date:  1989-12       Impact factor: 3.084

10.  Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

Authors:  S T Malik; D Martin; I Hart; F Balkwill
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.